Neovasc Inc. (NVCN): Price and Financial Metrics
GET POWR RATINGS... FREE!
NVCN Stock Summary
- Neovasc Inc's market capitalization of $29,294,498 is ahead of only 5.46% of US-listed equities.
- Neovasc Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 9.5% of US listed stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for NVCN comes in at -223.23% -- higher than that of only 1.32% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Neovasc Inc, a group of peers worth examining would be SMTC, BLI, QUIK, GBT, and CERS.
- NVCN's SEC filings can be seen here. And to visit Neovasc Inc's official web site, go to www.neovasc.com.
NVCN Valuation Summary
- NVCN's price/earnings ratio is -0.8; this is 102.19% lower than that of the median Healthcare stock.
- Over the past 166 months, NVCN's price/sales ratio has gone up 10.6.
- Over the past 166 months, NVCN's EV/EBIT ratio has gone down 0.9.
Below are key valuation metrics over time for NVCN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NVCN | 2021-08-31 | 11.7 | 11.6 | -0.8 | -0.7 |
| NVCN | 2021-08-30 | 12.0 | 11.9 | -0.8 | -0.7 |
| NVCN | 2021-08-27 | 12.4 | 12.2 | -0.8 | -0.7 |
| NVCN | 2021-08-26 | 11.8 | 11.7 | -0.8 | -0.7 |
| NVCN | 2021-08-25 | 11.7 | 11.6 | -0.8 | -0.7 |
| NVCN | 2021-08-24 | 11.5 | 11.4 | -0.8 | -0.6 |
NVCN Growth Metrics
- Its 2 year revenue growth rate is now at -51.99%.
- Its 3 year revenue growth rate is now at -78.02%.
- Its 4 year net income to common stockholders growth rate is now at 23.12%.
The table below shows NVCN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 2.547406 | -27.11277 | -24.88907 |
| 2021-09-30 | 2.302284 | -29.37562 | -23.15948 |
| 2021-06-30 | 2.225282 | -30.89349 | -25.85856 |
| 2021-03-31 | 1.876261 | -31.23124 | -26.75087 |
| 2020-12-31 | 1.957362 | -29.44186 | -28.69504 |
| 2020-09-30 | 2.009181 | -28.67625 | -36.62577 |
NVCN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- NVCN has a Quality Grade of F, ranking ahead of 0.31% of graded US stocks.
- NVCN's asset turnover comes in at 0.14 -- ranking 148th of 184 Medical Equipment stocks.
- 500 - Internal server error
The table below shows NVCN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.140 | 0.772 | -4.860 |
| 2019-12-31 | 0.189 | 0.781 | -4.740 |
| 2018-12-31 | 0.102 | 0.791 | -28.053 |
| 2017-12-31 | 0.089 | 0.355 | 0.408 |
| 2016-12-31 | 0.119 | 0.255 | 1.637 |
| 2015-12-31 | 0.234 | 0.301 | -3.837 |
NVCN Price Target
For more insight on analysts targets of NVCN, see our NVCN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
NVCN Stock Price Chart Interactive Chart >
NVCN Price/Volume Stats
| Current price | $6.09 | 52-week high | $23.38 |
| Prev. close | $6.00 | 52-week low | $4.59 |
| Day low | $5.94 | Volume | 28,600 |
| Day high | $6.31 | Avg. volume | 15,835 |
| 50-day MA | $6.21 | Dividend yield | N/A |
| 200-day MA | $12.17 | Market Cap | 16.49M |
Neovasc Inc. (NVCN) Company Bio
Neovasc is a specialty medical device company that develops, manufactures and markets products for the cardiovascular marketplace. The Company also sells a line of biological tissue products that are used as components in third-party medical products including transcatheter heart valves. The company was founded in 2000 and is based in Richmond, Canada.
Latest NVCN News From Around the Web
Below are the latest news stories about Neovasc Inc that investors may wish to consider to help them evaluate NVCN as an investment opportunity.
Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on March 10, 2022.Interested parties may access the conference call by dialing (877) ... |
Neovasc Announces German Reimbursement Renewal and Commercial ProgressVANCOUVER and MINNEAPOLIS, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation yet again for 2022. Additionally, the Company announced the 500th patient has been treated in Germany. New examination and treatment method |
Independent Publication Reports Neovasc Reducer(TM) Demonstrates Cost SavingsVancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 4, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc ReducerTM ("Reducer").The two analyses, authored by Americo Cicchetti, Graduate School of Health Economics and Management (ALTEMS) at the Catholic University of Sacro Cuore, Rome, included a budget impact analysis and a cost-utility analysis. T |
Independent Publication Reports Neovasc Reducer™ Demonstrates Cost SavingsVANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc Reducer™ (“Reducer”). The two analyses, authored by Americo Cicchetti, Graduate School of Health Economics and Management (ALTEMS) at the Catholic University of Sacro Cuore, Rome, included a budget impact analysis and a cost-utility analysis. The evaluations, both |
Neovasc Announces Complete Dismissal of Securities Class Action Complaint with PrejudiceVANCOUVER and MINNEAPOLIS, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313, filed in the United States District Court for the Southern District of New York. The consolidated amended complaint was dismissed in its entirety with prejudice and w |
NVCN Price Returns
| 1-mo | 4.64% |
| 3-mo | -43.57% |
| 6-mo | -48.02% |
| 1-year | -73.49% |
| 3-year | -94.87% |
| 5-year | -99.98% |
| YTD | -48.02% |
| 2021 | -50.76% |
| 2020 | -82.41% |
| 2019 | -9.83% |
| 2018 | -99.00% |
| 2017 | -65.32% |
Continue Researching NVCN
Want to do more research on Neovasc Inc's stock and its price? Try the links below:Neovasc Inc (NVCN) Stock Price | Nasdaq
Neovasc Inc (NVCN) Stock Quote, History and News - Yahoo Finance
Neovasc Inc (NVCN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...